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Background and purpose: Despite the availability of risk engines to determine cardiovascular 
risk, risk factor control is suboptimal. Using EURIKA data we compared risk factor control in 
Germany with that of 11 other European countries (rest of Europe [ROE]) to identify differences 
and opportunities for improvement.
Methods: EURIKA was a multinational, cross-sectional study in 12 European countries includ-
ing Germany from May 2009 to January 2010. Physicians’ attitudes to risk factor control based 
on the 2007 European guidelines on cardiovascular disease (CVD) prevention in a representative 
cohort of 7641 primary care outpatients aged $50 years with no CV disease and at least one 
major CV risk factor were determined.
Results: Compared to the ROE, German physicians were more frequently male (72.7% vs 
62.6%), had a higher mean age (51.7 ± 8.4 vs 47.0 ± 9.7 years), faced higher patient loads 
(37.9% vs 16.5% had .199 patients/week), and involved other health sector professionals 
(dieticians, psychologists) less (31.8% vs 41.0% in the ROE). The European Society of Cardiol-
ogy (ESC) guidelines on CVD prevention were more important for German physicians (60.6% 
vs 55.9%), while those who didn’t use them gave reasons for nonuse as too many (62.5% vs 
46.2%), too confusing, unrealistic, or not applicable to their patients. Risk engines were used 
less (54.5% vs 70.7%), with perceived lack of time (65.5% vs 60.2%) a frequent reason for 
nonuse. Risk factor control in German patients was inadequate (control rates: hypertension 
36.3%, dyslipidemia 30.4%, type 2 diabetes 40.6%, obesity 28.8%) but largely comparable to 
other ROE countries; however, physicians tended to overestimate control rates.
Conclusion: EURIKA provides comprehensive data on the status of primary prevention of 
CVD in clinical practice in Germany and reveals considerable potential for improving the 
primary prevention of CVD.
Keywords: cardiovascular risk factor, primary care
Introduction
Cardiovascular (CV) risk factor assessment is crucial in refining diagnosis and tailor-
ing treatment. When multiple risk factors have to be considered, the implications are 
more complex, because of their interrelationships and their less than additive impact 
on morbidity. To overcome this barrier, risk engines have been developed based on 
data from epidemiological studies, which consider multiple concurrent risk factors to 
come to an absolute risk estimate. Risk engines are also used to determine the impact 
of treatment on risk. Respective guidance has been laid down in major guidelines 
such as the European Society of Cardiology’s (ESC) Guideline on Cardiovascular 
Disease Prevention in Clinical Practice, the Guideline for the Management of Arterial 
Hypertension, and the Adult Treatment Panel III.1–3
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Given this degree of elaborated evidence and   guidance, 
it may be perceived as a surprise that cardiovascular dis-
ease (CVD) risk factors are largely uncontrolled in clini-
cal practice, as documented in registries such as REACH 
or EUROASPIRE.4,5 Although a previous edition of the 
  European guidelines recommended calculation of CVD risk 
with the SCORE, there has been no comprehensive assess-
ment of the extent of use of formal risk assessment systems, 
the selection of risk assessment tools and the use of such esti-
mates by physicians in clinical decision-making.6,7 Evidence 
is limited to less comprehensive surveys, usually limited to 
selected risk factors, or confined to a single country.8–12
In order to gain insight into the situation in Europe, 
including the attitude of physicians towards clinical guide-
lines for CVD prevention, cardiovascular risk assessment 
tools, and patient management, the European Study on Car-
diovascular Risk Prevention and Management in Usual Daily 
Practice (EURIKA; NCT00882336) was conducted.13–17 The 
availability of this dataset provides a unique opportunity to 
compare the German data with a number of other   European 
countries; to identify differences and opportunities to 
improve CVD prevention.
Methods
EURIKA was a multinational, cross-sectional study 
conducted in 12 European countries (Austria, Belgium, 
France, Germany, Greece, Norway, Russia, Spain, Sweden, 
  Switzerland, Turkey, and the UK) from May 2009 to January 
2010. All participating patients provided written informed 
consent. The study design was published by Rodriguez-
Artalejo et al and the EURIKA Investigators, and complies 
with local regulations for clinical research and was approved 
by the appropriate clinical research ethics committee in each 
participating country – which corresponded to the Ethics 
Committee of the Friedrich-Alexander-University Erlangen-
Nürnberg in Germany.13
Physician and patient selection
Primary care physicians, cardiologists, endocrinologists, 
diabetes specialists, and internal medicine specialists were 
selected at random to represent practitioners involved in CVD 
prevention in primary care centers or outpatient clinics in 
each country using the OneKey database.18 OneKey, a large 
database containing information on the demographics and 
specialties of physicians in each country, obtains information 
from directories of health centers, and is drawn from official 
web sources, registries, and addresses of health administra-
tions and professional organizations in the public and   private 
sectors, to make up the physicians panel or universe of 
  doctors potentially participating in the study. This database 
lists 74,963 eligible physicians for Germany.
The selection criteria for patients were those aged $50 years 
who were free from clinical CVD, with at least one of the 
classic CVD risk factors (hypertension, dyslipidemia, 
diabetes, obesity, or tobacco consumption documented in 
the clinical record). Physicians received a randomization 
list to select a sample of patients cited for medical visits   
each day during the study period.
Variables collected
Information was collected at two levels. At the physician 
level, each physician answered a questionnaire regarding 
typical daily practice and opinions about cardiovascular 
risk management guidelines and global risk assessment 
tools. A patient-specific questionnaire captured information 
from clinical records and patients’ interviews regarding 
sociodemographic data, CVD risk factors, current medica-
tions, comorbidity, and other aspects of CVD prevention 
and   management. Anthropometry and blood pressure (BP) 
readings were obtained under standardized conditions for 
each patient. Further, a fasting blood sample was obtained 
on the same day as the outpatient consultation or, if this was 
not possible, the following day. The blood samples were sent 
to a central laboratory in Belgium (Bio Analytical Research 
Corporation, Ghent, Belgium) for assessment of serum lipids, 
apo AI, apo B, hs-CRP, uric acid, HbA1c, and creatinine.
A 10% random sample of all centers with participating 
physicians underwent a site visit for data monitoring and 
audit to ensure data quality.
Treatment goals for CVD risk factors
Treatment goals were evaluated in accordance with   European 
guidelines, based on data from either the physical examina-
tion or the blood sample drawn at the study visit.1,2 Target 
BP was systolic/diastolic blood pressure (SBP/DBP) 
,140/90 mm Hg, except for patients with diabetes where it 
was ,130/80 mm Hg. Target lipid levels were ,5 mmol/L 
(190 mg/dL) total cholesterol and ,3 mmol/L (115 mg/dL) 
LDL-cholesterol, except for patients with diabetes where 
the goal was ,4.5 mmol/L (175 mg/dL) total cholesterol, 
and ,2.5 mmol/L (100 mg/dL) LDL-cholesterol. The target 
HbA1c was ,6.5%, and the target fasting plasma glucose 
(FPG) was ,6.1 mmol/L (110 mg/dL) in all patients. The 
target body mass index (BMI) was ,30 kg/m2 and the target 
waist circumference (WC) was ,102 cm in men and ,88 cm 
in women.
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We calculated the 10-year risk of fatal CVD for each 
patient using the SCORE equation, based on age, sex, cur-
rent smoking, total cholesterol, and SBP measured at the 
study visit. These values were independent of treatment. We 
used the equation developed for low-risk regions for patients 
in Belgium, France, Greece, Spain, and   Switzerland, and 
the equation for high-risk regions for patients in   Austria, 
  Germany, Norway, Russia, Sweden, Turkey, and the UK.2,4,19,20 
A 10-year risk of CVD death $5% was regarded as   
high.2,21
Statistical analysis
Responses were collated and statistical analysis performed 
using SAS software (v 9.1; SAS Institute Corp, Cary, NC). 
The descriptive analysis contained statistical indicators 
as follows: qualitative variables were described by num-
ber of observed values (N), absolute (n) and relative (%) 
frequencies per class, and percentage confidence intervals 
using SAS surveyfreq procedure. Patients with missing 
data were not included in the percentage calculation and 
the number of missing values was specified. Quantitative 
variables were described by number of observed   values (N), 
arithmetic mean and confidence interval, sample   standard 
deviation (SD), median, minimum and maximum, number 
of missing values using SAS survey means procedure. 
The number of out-of-range values was specified if   
applicable.
Results
Overall, 806 physicians participated in EURIKA, 66 of 
whom were located in Germany and 740 in the rest of the 
11 European countries (the ROE). These physicians docu-
mented the clinical risk profile of 7641 patients (678 in 
Germany and 6963 in the ROE). Physician response 
rate was 8.0% in Germany (7.0% in the ROE, excluding 
  Russia, where physician and patient response was 100%) 
and patient response rate was 49.0% (60.6% in the ROE, 
excluding Russia).
Physicians’ attitudes toward risk  
factor control
Out of a total of 66 physicians recruited in Germany, 48 
were male (72.7%) and 25 physicians were aged ,50 years 
(37.9%) (Table 1). Compared to other participating countries, 
German physicians were more frequently male and had a 
higher age (in the ROE, 62.6% were male, and 58.8% were 
aged ,50 years). The number of physicians working together 
was smaller (,5 physicians) in Germany (68.2% vs 44.5% 
in the ROE), but the number of patients treated per week was 
substantially higher in Germany than in the ROE (37.9% vs 
16.5% treated .199 patients per week).
Overall, 87.9% of physicians in Germany (58/66) 
reported that they followed European guidelines on the 
treatment of cardiovascular risk factors, which was approxi-
mately comparable with other European countries (87.4%; 
647/740) (guidelines specified in Figure 1). German physi-
cians usually referred to the ESC Guideline on Cardiovas-
cular Disease Prevention in Clinical Practice, and the ESC 
Guideline for the Management of Arterial Hypertension, 
while there was substantial use of localized guidelines in 
other countries (3.0% in Germany vs 18.3% in the ROE).1,2 
Out of about 12% of physicians who indicated they did not 
use the guidelines (Table 2), 62.5% of those in Germany 
indicated that there are too many guidelines, a view shared 
by fewer physicians in other countries (46.2% in the ROE). 
In these countries, a lack of knowledge (29.0%), confusion 
over how to use the guidelines (9.7%), and a view that the 
guidelines were unrealistic (19.4%) were important reasons 
given for nonuse.
Table 1 Physician demographics
Germany 
physicians (%)
Rest of Europe 
physicians (%)
Physicians (total) 66 740
Sex
  Male 48 (72.7) 463 (62.6)
  Female 18 (27.3) 277 (37.4)
Mean age (years ± SD) 51.7 ± 8.4 47.0 ± 9.7
Specialty
  Primary care 34 (51.5) 480 (64.9)
  Cardiology 7 (10.6) 87 (11.8)
  Internal medicine 21 (31.8) 126 (17.0)
    Diabetes or  
endocrinology
1 (1.5) 23 (3.1)
  Other 3 (4.5) 24 (3.2)
Main work setting
  Urban 48 (72.7) 477 (64.5)
  Suburban 7 (10.6) 114 (15.4)
  Rural 11 (16.7) 148 (20.0)
  Did not specify 0 (0.0) 1 (0.1)
Number of patients treated per week
 , 50 1 (1.5) 124 (16.8)
  50–99 12 (18.2) 266 (35.9)
  100–199 28 (42.4) 228 (30.8)
 . 199 25 (37.9) 122 (16.5)
Number of physicians in working environment
 , 5 45 (68.2) 329 (44.5)
  5–9 8 (12.1) 134 (18.1)
  10–19 6 (9.1) 121 (16.4)
 . 19 7 (10.6) 155 (20.9)
  Did not specify 0 (0.0) 1 (0.1)
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Physicians were also asked whether they routinely used 
global risk assessment tools to calculate cardiovascular risk 
in their patients, to which 54.5% in Germany (70.7% in the 
ROE) responded that they did. The most commonly used 
risk engines were the ESC SCORE, followed by algorithms 
outlined in the ESH/ESC hypertension guidelines (Figure 2). 
Major differences between Germany and the ROE were found 
in the use of the original Framingham score (Germany , the 
ROE). The most common reasons given for not using scores 
were time constraints followed by little value, and a lack of 
knowledge on how to use them.
Patient characteristics and degree  
of risk factor control
A total of 678 patients were recruited in Germany, in which 
the mean age was 65.3 ± 8.9 years, and in which 49.1% 
were male. On average, patients were slightly older than in 
the ROE (63.0 ± 8.9 years) and substantially more patients 
were aged at least 65 years (54.4% vs 39.5%). Frequent 
comorbid risk factors of the participating German patients 
were hypertension (81.0%), dyslipidemia (59.6%), obesity 
(49.0%), and diabetes mellitus (37.8%), of which hyperten-
sion, obesity, and diabetes mellitus were more common 
than in the ROE at 71.9%, 43.0%, and 25.7%, respectively. 
Overall, 57.1% of German patients (while only 38.4% in 
the ROE) were considered to be at high cardiovascular risk 
based on a SCORE total of $5% (Table 3).
Actual German control rates of the main risk factors 
were 36.3% for hypertension, 30.4% for dyslipidemia (total 
cholesterol and LDL-c), 40.6% for type-2 diabetes (HbA1c), 
and 28.8% for obesity (based on BMI). Although there were 
only a few statistically significant differences in control rates 
between Germany and the ROE (Figure 3), the control of 
dyslipidemia was worse in Germany (odds ratio [OR]: 0.74; 
95% confidence interval [CI]: 0.52–1.04). By contrast, the 
control of dyslipidemia was particularly good in the UK 
(OR: 3.60; 95% CI: 2.16–4.27), and Belgium (OR: 1.69; 
95% CI: 1.22–2.34). Countries with particularly good con-
trol of hypertension (France and Greece) used more angio-
tensin receptor blockers (ARB: 54.4%/59.1% vs 32.2% in 
  Germany), fewer beta blockers (26.5%/23.5% vs 53.9%), and 
fewer ACE inhibitors (16.4%/25.4% vs 47.0%). In Belgium, 
where control of blood glucose was particularly effective, 
there was a pronounced use of metformin in comparison to 
Germany (69.4% vs 55.9%). Gross differences in the use of 
lipid-lowering drugs were not found, although control rates 
were higher in Belgium and the UK. Overall, there was 
a trend to overestimate control rates among physicians in 
participating countries.
Perspectives to improve care
Physician-derived tips on how to improve behavioral risk 
factors are displayed in Table 4. Of particular concern to 
German physicians was that they need to spend more time 
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Figure 1 Physicians’ use of guidelines for the management of cardiovascular risk factors.
Notes: ESC CVD Prevention, European Society of Cardiology (ESC) Guideline on Cardiovascular Disease Prevention in Clinical Practice; ESC/ESH Hypertension, ESC Guideline for 
the Management of Arterial Hypertension; ATP III, Adult Treatment Panel III; JNC VII, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure.1–3,45 Other guidelines not specified.
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with the patient (83.3% vs 74.1%), which was confirmed in 
strong recommendations to develop a sympathetic alliance 
with the patient, and to listen carefully. This was also directly 
related to patient load, which was substantially higher in 
Germany than in the ROE (37.9% vs 16.5% of physicians 
see more than 199 patients per week).
On the other hand, German physicians tended to involve 
others less. While they had a strong preference for specific 
patient courses (42.4% vs 21.5%), they were less likely to 
involve nurses (21.2% vs 33.2%) or other health care staff 
(dieticians, social workers, psychologists) (31.8% vs 41.0%) 
than colleagues in the ROE.
Discussion
Taken together, the present analysis of CVD prevention and 
management strategies for at-risk patients in Germany dem-
onstrates the high degree of unmet medical need and a lack of 
control. Key findings were: (1) physicians in Germany were 
more frequently older males working in private practice, facing 
a higher patient load. They were less likely to involve other 
health care staff in their patient management. (2) The ESC 
guidelines on cardiovascular disease prevention were more 
important for German physicians than other local documents, 
and those not referring to the guidelines gave reasons for 
nonuse as being that the guidelines were too numerous, were 
partially confusing, or even unrealistic and/or not applicable 
to their patients’ specific situations. Risk engines are used, 
Table 2 Physicians’ reasons for not using clinical guidelines and 
global risk assessment tools, and beliefs about the limitations of 
risk assessment tools
Germany 
physicians 
N (%)
Rest of Europe 
physicians 
N (%)
Reasons for not using clinical guidelines n = 8 n = 93
  There are too many guidelines 5 (62.5) 43 (46.2)
  Time constraints 3 (37.5) 31 (33.3)
  Do not know them 1 (12.5) 27 (29.0)
  Guidelines were unrealistic 6 (75.0) 18 (19.4)
  Poor acceptance by the patient 3 (37.5) 11 (11.8)
  Guidelines are confusing 2 (25.0) 9 (9.7)
  Do not agree with recommendations 3 (37.5) 2 (2.2)
Reasons for not using global risk  
assessment tools
n = 29 n = 211
  Time constraints 19 (65.5) 127 (60.2)
  Risk assessment tools are of little use 9 (31.0) 44 (20.9)
  Do not know how to use 2 (6.9) 46 (21.8)
    Do not know how to proceed after  
risk assessment
0 (0.0) 10 (4.7)
  Other 6 (20.7) 25 (11.8)
Believe risk assessment tools have  
limitations
n = 64 n = 725
  Yes 51 (79.7) 520 (71.7)
  No 13 (20.3) 205 (28.3)
Limitations of risk assessment tools* n = 47 n = 510
  Miss important risk factors 39 (83.0) 474 (92.9)
    Do not allow calculation of risk in the 
elderly
36 (80.0) 344 (67.5)
  Assess risk over too long a time period23 (52.3) 244 (47.8)
  Overestimate risk 21 (45.7) 176 (34.5)
Note: *Missing responses were considered negative.
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Figure 2 Physicians’ use of global risk assessment tools (of those using these tools).
Notes:  ESC  Score;  ESC/ESH  Hypertension,  ESC  Guideline  for  the  Management  of  Arterial  Hypertension;  Framingham  study;  Framingham  Coronary  Risk  Score.2,6,7,38 
*Locally calibrated version of the Framingham study score. Other guidelines not specified.
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although a perceived lack of time was a frequent reason given 
for their nonuse. (3) Risk factor control was inadequate but 
largely comparable with the mean of other countries; however, 
physicians tended to overestimate control rates. (4) Population 
risk for CVD mortality in Germany was attributed to diabetes 
and hypertension more frequently than in other countries.
Workload of German physicians
Out of a total of 806 physicians in EURIKA, 147 reported 
treating .199 patients per week (18.2%). This finding is in 
line with previous research documenting a mean workload 
of up to 73 patients per day.22 This is of particular concern, 
since workload has been identified as a main barrier for more 
vigorously pursued CVD prevention.23,24 It is also worrisome 
because “time constraints” was among the most important 
reasons for not using guidelines or global risk assessment tools 
in the present survey. It was further determined in an Irish sur-
vey that the number of elderly patients was considered to be a 
major factor in determining workload, something that must be 
seriously considered given the ongoing demographic change 
in Germany.25 High workload is also a major determinant of 
dissatisfaction among primary care physicians.26
So what can be done?
(1) A recent study which aimed at determining the opti-
mal size of practices in order to balance both physician 
workload and quality of care provided, demonstrated that 
the optimum average physician workload was found in the 
largest   practices.27 This may favor increasing the number of 
physicians in a single practice, which was lower in Germany 
in EURIKA (68.2% in Germany vs 44.5% in the ROE who 
reported   having ,5 colleagues in their work setting). (2) Use 
of disease management programs (DMPs) has been shown 
to decrease workload and increase practice satisfaction 
while improving the quality of care provided in primary care 
practices in 13 urban counties in California.28 DMPs have 
already been installed in Germany for selected indications, 
and recent reports have shown improved health care processes 
and risk factor control in diabetic patients.19,20 Miksch et al 
have even suggested reduced mortality rates for diabetic 
patients enrolled in DMPs, but were cautious in claiming a 
causal relationship.29
Useful guidance for clinical practice  
and use of risk engines
Guidelines are usually prepared by specialists in the field, and 
aim to mirror current evidence to the best possible extent. 
They further aim at being exhaustive, making them a proper 
reference for specialized physicians. Given these complexi-
ties, it is not surprising to find that translation of guidelines 
into primary care practice might be insufficient. For example, 
the German follow-up of the Hypertension Evaluation Project 
clearly demonstrated inadequate knowledge of the diagnosis 
and treatment of arterial hypertension.30 Further, there is evi-
dence that deficiencies in treatment quality appear to be the 
result of inadequate implementation of existing cardiologic 
treatment recommendations (among other factors).21,31 On 
the other hand, the results of a recent survey indicated that 
there is essentially no difference in the treatment provided by 
physicians knowledgeable in the guidelines and those who 
were less familiar.11
Against a background of these considerations, it appears 
noteworthy that 87.9% of all physicians interviewed in 
  Germany for the present survey reported following guide-
lines on the treatment of cardiovascular risk factors. This 
was about comparable with other European countries. On 
the other hand, while self-indicating a fairly good control 
of risk factors, a maximum of 40% of patients were actually 
controlled when hypertension, dyslipidemia, type-2 diabetes, 
and obesity were considered. This is in agreement with the 
aforementioned, giving rise to speculation that the guidelines 
Table 3 Sociodemographic and clinical patient characteristics
Germany 
patients (%) 
n = 678
Rest of Europe 
patients (%) 
n = 6963
Sex
  Male 333 (49.1) 3363 (48.3)
  Female 345 (50.9) 3600 (51.7)
Age (years ± SD)
  Mean 65.3 ± 8.9 63.0 ± 8.9
 , 65 years 309 (45.6) 4210 (60.5)
 $ 65 years 369 (54.4) 2753 (39.5)
Blood pressure (mm Hg ± SD)
  SBP (mean) 135.4 ± 17.1 135.0 ± 16.5
  DBP (mean) 80.7 ± 9.5 80.0 ± 10.0
Alcohol
  U/week ± SD 6.4 ± 11.8 5.6 ± 11.3
Smoking (%) 325 (47.9) 3373 (48.4)
  Current (%) 112 (16.5) 1516 (21.8)
  Former (%) 212 (31.3) 1859 (26.7)
Hypertension (%) 549 (81.0) 5006 (71.9)
Dyslipidemia (%) 404 (59.6) 4005 (57.5)
Diabetes mellitus (%) 256 (37.8) 1792 (25.7)
Obesity (%) 332 (49.0) 2992 (43.0)
Physical inactivity (%) 82 (12.1) 1431 (20.6)
Living alone (%) 146 (21.6) 1313 (18.9)
High CV risk* (score $5%) (%) 87 (57.1) 2677 (38.4)
Note: *High CV risk (SCORE $5%) – calculation of SCORE risk was based on the 
following data: age, sex, systolic blood pressure, and total cholesterol values at the 
study visit, and smoking status.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
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might have to be more directive instead of targeting evidence 
completeness.
The same considerations may apply to the use of 
risk engines in clinical practice. In previous evaluations, 
for example, CHD risk in a population with diabetes 
was underestimated by the Framingham and UKPDS 
risk functions.32–34 Previous research also showed an 
  overestimation of CHD risk predicted by the UKPDS risk 
function during 5 years of follow-up, the SCORE risk func-
tion during 10 years of follow-up, and the Framingham risk 
function in European populations.35–38 This was reflected in 
EURIKA by a number of physicians considering the “risk 
assessment tools to be of little use” (31.0% in Germany vs 
20.9% in the ROE).
0123456
GER HT
FRA HT
GRE HT
GER DL
BEL DL
UK DL
GER DM
BEL DM
GER OBES
GRE OBES
Single country better Europe better
OR 1.09 (95%CI 0.84−1.40)
OR 1.37 (95%CI 1.04−1.79)
OR 1.68 (95%CI 1.28−2.22)
OR 0.74 (95%CI 0.52−1.04)
OR 1.69 (95%CI 1.22−2.34)
OR 3.03 (95%CI 2.16−4.27)
OR 1.21 (95%CI 0.78−1.87)
OR 1.66 (95%CI 1.05−2.63)
OR 1.25 (95%CI 0.85−1.83)
OR 1.82 (95%CI 1.25−2.65)
Figure 3 Control of treated hypertension (,140/90 mm Hg), dyslipidemia (total cholesterol , 5 and LDL-c , 3 mmol/L),* type 2 diabetes (HbA1c , 6.5%), and obesity 
(BMI , 30 kg/m2) in special countries versus the average control rate in all countries.
Notes: *Patients with diabetes: ,130/80 mm Hg; ,4.5 mmol/L, and ,2.5 mmol/L (100 mg/dL).
Abbreviations: BEL, Belgium; FRA, France; GER, Germany; GRE, Greece; UK, United Kingdom; DL, dyslipidemia; DM, diabetes mellitus; HT, hypertension; OBES, obesity.
Table 4 Communication tips usually used for the management of behavioral risk factors (physicians)
Germany 
physicians (%) 
n = 66
Rest of Europe 
physicians (%) 
n = 729
Physician-centered tips
  Spend enough time with patient 55 (83.3) 540 (74.1)
  Speak to patient with his/her own language 47 (71.2) 565 (77.5)
  Develop a sympathetic alliance with the patient 55 (83.3) 518 (71.1)
  Involve the family in the treatment 37 (56.1) 325 (44.6)
Patient-centered tips
  Listen carefully, recognize strength and weakness in the patient’s attitude to illness and lifestyle 50 (75.8) 504 (69.1)
  Ensure that the patient understands the relationship between lifestyle and disease 58 (87.9) 609 (83.5)
  Offer specific courses to patient 28 (42.4) 157 (21.5)
  Accept the patient’s view of his/her disease, allow expression of worries 45 (68.2) 471 (64.6)
    Acknowledge that changing life-long habits can be difficult, and gradual change that is sustained  
is often more useful
53 (80.3) 550 (75.4)
  Gain commitment to lifestyle change 28 (42.4) 329 (45.1)
  Involve patient in identifying the barriers to change 34 (51.5) 334 (45.8)
  Involvement of others
Involve other health care staff (nurse) 14 (21.2) 242 (33.2)
  Involve other health care staff (dietician, social worker, psychologist) 21 (31.8) 299 (41.0)
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On the other hand, even among those who considered risk 
engines to be useful, there was a belief that “risk assessment 
tools have limitations” (79.7% in Germany vs 71.7% in the 
ROE) and the perception that engines “miss important risk 
factors” (83.0% in Germany vs 92.9% in the ROE) and 
do “not allow calculation of risk in the elderly” (80.0% in 
Germany vs 67.5% in the ROE). It essentially reflects that 
physicians feel that the results are of little use in their daily 
clinical practice. It appears difficult to tell which steps must 
be taken to improve the acceptance of these risk engines, 
but a local validation and the demonstration that risk scores 
may actually help in refining and improving therapies and 
outcomes in particular would certainly be of help. However, 
these data are scarce.
Risk factor control is inadequate
EURIKA has documented a largely inadequate control of 
risk factors in Germany, thus resembling previous reports 
on insufficient control rates of hypertension, diabetes, and 
obesity.39–41 Additionally, control is no better (but also no 
worse) compared with the average of the 11 other European 
EURIKA countries.
However, a closer look reveals that countries such as 
France, Greece, Belgium, and the UK do better in the control 
of single risk factors, while others are worse (Russia, Sweden, 
and Turkey). From a patient perspective, differences in age 
(54.4% vs 39.5% were aged at least 65 years in Germany) 
and gender (although substantially less likely at 49.1% vs 
48.3% in ROE) may result in differences in control rates, due 
to advanced disease or different treatment patterns. Patients 
in Russia, Turkey, and Austria are considerably younger (at 
58.3 years, 59.4 years, and 61.9 years, respectively), while in 
other countries such as Greece, Sweden, Switzerland, and the 
UK, the patients are as old as those in Germany (65.3%).14 
Furthermore, patients in Russia were much less likely to 
be male (31.8%), while a substantial proportion in France 
were (54.8%).14 These differences in sociodemographic 
characteristics are, however, not uniform and require further 
exploration of differences between countries which may 
explain these surprising findings.
Amongst these, the control of dyslipidemia in the UK 
is particularly noteworthy (OR: 3.03; 95% CI: 2.16–4.27): 
compared to the ROE, dyslipidemia control rate in Germany 
is rather poor (OR: 0.74; 95% CI: 0.52–1.04). The study 
delivered two possible explanations for this finding: the 
percentage of German dyslipidemia patients receiving lipid-
lowering drug treatment is smaller than in the ROE (65% vs 
75%), and newer statins such as atorvastatin or rosuvastatin 
are prescribed less for German patients. On the other hand, 
however, the UK is the only country where simvastatin is 
available at a low 10 mg dose without prescription (over the 
counter, OTC).42 It has been suggested that while it may not 
actually increase OTC use by patients themselves, it may have 
resulted in an overall increase in statin prescription rates by 
GPs in the UK.43
Furthermore, hypertension control rates are above aver-
age in France (OR: 1.37; 95% CI: 1.04–1.79) and Greece 
(OR: 1.68; 95% CI: 1.28–2.22). We found ARB use was 
particularly high, and beta blocker and ACE inhibitor use was 
low in these countries. Based on these data, it is uncertain 
whether or not this may actually lead to a causal improvement 
in blood pressure control, but ARBs have been associated 
with a particularly high rate of treatment compliance and 
long-term blood pressure control in comparison with beta 
blockers, for example.44
Limitations
The lack of a comprehensive framework for physician 
sampling in all European countries might be perceived as a 
potential limitation of the EURIKA study. We used the best 
available approximation – the OneKey database – which 
is the largest available database of practicing physicians in 
Europe, although it is not statistically representative of all 
European physicians. Further, the participation rate among 
invited physicians was not optimal, which may have resulted 
in a bias towards physicians being more involved in CVD 
prevention, suggesting that results obtained might represent 
a best-case scenario that might slightly overestimate the 
control of CVD risk factors and quality of care in usual 
clinical practice.
On the other hand, the large number of participating 
practitioners, coverage of major medical specialties and 
work-settings, and random selection of patients, suggests that 
the EURIKA study makes an important contribution to the 
identification of barriers in the diagnosis and management 
of cardiovascular disease, and is as accurate as practically 
possible.
Conclusion
EURIKA provides comprehensive data on the situation of 
primary prevention of CVD in clinical practice in Germany. 
It reveals a considerable potential for improving the primary 
prevention of CVD. Our data suggest that (1) a way to reduce 
patient load must be found, (2) guidelines including those for 
CVD prevention must be tailored to meet the need of   primary 
care physicians, in order to increase guideline   acceptance in 
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clinical practice, and (3) differences in performance between 
countries may point towards determinants important for 
increased risk factor control.
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